Richard Caligaris

QurAlis' CSO Dan Elbaum and Sandy Hinckley, vp and head of discovery, took the #ALSIceBucketChallenge at the #ALSNexus conference to help continue to raise awareness and support for ALS research with the goal of discovering and developing new treatments and ultimately a cure. #icebucket10 #precisionmedicine #neurodegenerativediseases #neurologicaldiseases

78

1 Comment

Diakonos Oncology CFO Anthony Baldor is at #BIO24 this week to make a company presentation and meet with potential partners and investors. For those interested in learning more about Diakonos’ unique dendritic cell vaccines for cancer, we can be reached through the BIO ONE Partnering System. Mr. Baldor’s company presentation takes place on Tuesday, June 4th at 3:00 pm PT in Company Presentation Theater 2 at the San Diego Convention Center. Mr. Baldor’s presentation will include a review of Diakonos’ highly differentiated double-loaded autologous dendritic cell vaccines for cancer, and an operational update on the company’s plans for growth, including clinical development outlook and expansion of its leadership team. Diakonos recently completed a Phase 1 trial of DOC1021, its lead vaccine for glioblastoma multiforme (GBM), and is planning a Phase 2 study. The US Food and Drug Administration has granted Fast Track and Orphan Drug status for DOC1021. Two other clinical trials are under way with dendritic cell vaccines targeting pancreatic cancer and angiosarcoma. “We are very excited about the results of our Phase 1 trial for GBM,” Mr. Baldor said. “Data observed to date give us great confidence in our dendritic cell vaccines and their potential to treat a broad range of solid tumor cancers, including the most deadly. Twelve month survival is currently at 90% for evaluable patients, and the therapy is well tolerated.” Diakonos’ dendritic cell vaccines activate robust cytotoxic TH1 cell signaling pathways that better harness a patient's immune system to target and eliminate cancer cells by initiating a natural immune response. This is achieved without any genetic modification of the patient’s immune cells, which greatly simplifies the manufacturing process and significantly reduces costs when compared to leading cell therapy approaches. Visit our we site: diakonosoncology.com to learn more. #cancerresearch #cancer #biopharma #clinicaltrials https://lnkd.in/dET5pqbD

25

5 Comments

BeiGene, a global oncology leader, and NewBridge Pharmaceuticals have jointly decided to conclude their successful partnership. This strategic decision aligns with BeiGene’s vision to expand its presence and directly manage operations in the MENA region. The collaboration, which began in 2020, focused on sales, distribution, and commercialization of BRUKINSA® (Zanubrutinib) in the MENA region, resulting in approvals by health authorities in multiple territories and currently marketed in several regions, with more approvals anticipated. The transition will occur on a country-by-country basis starting in June 2024 and completing by March 31, 2025, with BeiGene taking over all customer-facing activities from June 11, 2024. This strategic shift marks a significant milestone for BeiGene as it continues to expand its global presence, aiming to achieve groundbreaking advancements in the treatment of solid tumors and hematological cancers by 2025, reinforcing its dedication to providing cutting-edge cancer therapies worldwide. #Oncology #CancerCare #Healthcare #MedicalInnovation #Pharmaceuticals #GlobalExpansion #Partnership #MENARegion #Brukinsa #BeiGene #NewBridgePharma #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #MarketEntryStrategy #CompetitiveIntelligence #PartnerIdentification #StrategySupport #ConferenceCoverage Detailed News: https://lnkd.in/d-UrURNN Follow our page for more industry updates: https://lnkd.in/de5zNWmK

22

2 Comments

🌐 The Lynx.MD team is heading to San Diego for DIA 2024. Drug discovery is a complex, lengthy process. DIA brings together the life sciences community to discuss innovations accelerating advancements, bringing therapies to care faster. Reach out to the Lynx.MD team, including Collin Labar, on LinkedIn to learn more about how our partners are using Lynx.MD’s rich structured and unstructured data sets to find insights addressing medical affairs and market access. See you at #DIA2024! 🌟 #Data #Research

17

Are you attending #BIO2024 today in San Diego? If you’ll be there, make sure to pop by for our session where our Executive Biotech Advisor, Carin Canale-Theakston, will share "An Insider Look at Top Deals from 2023” at 3pm-4pm PST. The session offers valuable insights into biotech collaborations and innovations.   Looking forward to seeing old friends and making new connections at the conference today! #Biotech #InvestorRelations #LifeSciences #CorpComms #InizioEvokeComms

39

1 Comment

Congrats to Brise Pharma for completing nearly USD 20 million in Pre-A and Pre-A+ rounds of financing! We at Qiming, a consistent supporter of the company's Seed and Angel rounds, have continued to participate in this round. The raised funds will be used for the development of Brise's pipeline in preclinical and clinical stages, particularly to accelerate the clinical trials of BR005, China's first independently developed CGRP class small molecule drug. Brise Pharma is committed to developing innovative, high specificity pain treatments, especially for severe chronic pain conditions – focusing largely on addressing unmet clinical needs for facial pain, musculoskeletal pain and neuropathic pain. Their vision is to provide safe, effective, and convenient pain management solutions to patients worldwide suffering from chronic pain, already having two drugs in clinical stages. Stay tuned for more updates on their incredible journey! https://lnkd.in/e3AAQe4T #QMportfolio #QMhealthcare #financing ##BrisePharma #QimingVenturePartners #InvestInInnovation #ChronicPainManagement #ClinicalTrials

10